Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.

NCT04721821 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7807

Last updated 2024-04-12

Study results available
· View outcomes & findings →

Summary

This study is to investigate if there has been a shift in treatment with tofacitinib, assessing real world patient data and entered in the Corrona registry between 2016 and 2020.

Conditions

  • Arthritis Rheumatoid

Interventions

DRUG

Tofacitinib

Patients who received Tofacitinib for RA

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-22
Primary Completion
2021-11-29
Completion
2021-11-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04721821 on ClinicalTrials.gov